Shentu, Yue
https://orcid.org/0000-0002-9547-1387
Mayo Clinic
Merck & Co., Inc., Rahway, NJ, USA (United States)
Citations 3
Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.
Baas, Paul, Molina, Julian R. , Kim, Joo-Hang , Arvis, Catherine Dubos, Ahn, Myung‐Ju , Fidler, Mary J. , Castro, Gilberto de , Garrido, Marcelo , Shentu, Yue , Lubiniecki, Gregory M., Im, Ellie, Baas, Paul, Garon, Edward B. , Herbst, Roy S. , Felip, Enriqueta , Perez‐Gracia, José Luis , Han, Ji-Youn , Majem, Margarita , Barlési, Fabrice , Kim, Dong‐Wan
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9015-9015
Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.
Baas, Paul, Molina, Julian R. , Kim, Joo-Hang , Arvis, Catherine Dubos, Ahn, Myung‐Ju , Fidler, Mary J. , Surmont, Veerle, Castro, Gilberto de , Shentu, Yue , Dolled‐Filhart, Marisa, Im, Ellie, Herbst, Roy S. , Baas, Paul, Perez‐Gracia, José Luis , Felip, Enriqueta , Kim, Dong‐Wan , Han, Ji-Youn , Majem, Margarita , Garrido, Marcelo , Garon, Edward B.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3030-3030
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.
Molina, Julian R. , Kim, Joo-Hang , Arvis, Catherine Dubos, Ahn, Myung‐Ju , Fidler, Mary J. , Gubens, Matthew A. , Castro, Gilberto de , Shentu, Yue , Im, Ellie, Lubiniecki, Gregory M., Baas, Paul, Garon, Edward B. , Herbst, Roy S. , Kim, Dong‐Wan , Felip, Enriqueta , Perez‐Gracia, José Luis , Han, Ji-Youn , Majem, Margarita , Garrido, Marcelo , Baas, Paul
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9024-9024